Table SI. Location of metastases at the onset of regorafenib treatment.

Patient no.	Liver	Pancreas	Lymph nodes	Small intestine	Peritoneum	Stomach	Mediastinum	Abdominal wall	Retroperitoneal space
1	X								
2	X		X						
3	X	X	X						
4	X			X					
5	X		X		X		X		
6	X								
7	X				X				
8	X				X				
9	X				X				
10	X			X				X	
11					X				
12	X								
13	X				X				
14	X				X			X	
15	X				X				X
16					X				
17	X				X				
18	X				X		X		
19	X					X			
20	X								
21	X								

Table SII. Adverse event characteristics in patients with regorafenib-induced hepatic toxicity.

Patient no.	Baseline parameters CTCAE grade	Maximum CTCAE grade	Pattern
1	ALT: 0, AST: 0, AP: 2, γ-GT: 3, Bili: 1	ALT: 3, AST: 4, AP: 2, γ-GT: 3, Bili: 2	Hepatocellular
2	ALT: 0, AST: 0, AP: 0, γ-GT: 0, Bili: 0	ALT: 0, AST: 0, AP: n.a., γ-GT: n.a., Bili: 1	Cholestatic
3	ALT: 1, AST: 1, AP: 2, γ-GT: 3, Bili: 2	ALT: 1, AST: 1, AP: 2, γ-GT: 3, Bili: 3	Mixed
4	ALT: 0, AST: 1, AP: 0, γ-GT: 0, Bili: 0	ALT: 4, AST: 4, AP: 1, γ-GT: 3, Bili: 3	Mixed
5	ALT: 0, AST: 0, AP: 0, γ-GT: 0, Bili: 0	ALT: 2, AST: 2, AP: 1, γ-GT: 3, Bili: 3	Mixed

CTCAE, Common Terminology Criteria of Adverse Events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; γ-GT, γ-glutamyltransferase; Bili, bilirubin; n.a., not available.